Drug Trial Radar · NCT07561554
Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation
Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
159
Planned (sponsor's estimate)
Start
Mar 6, 2026
Primary completion
Dec 2, 2028
Study completion Dec 2, 2028
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK42360-Na when given orally in patients with active BRAF V600 mutation locally advanced or metastatic Solid Tumors.
Conditions
- Solid Tumors (Phase 1)
Interventions
HSK42360-NaDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTDTime frame: Up to approximately 52 months
- DLTsTime frame: Up to approximately 52 months
- AEsTime frame: Up to approximately 52 months
- RP2DTime frame: Up to approximately 52 months
- ECOG Performance Status ScaleTime frame: Up to approximately 52 months
- Karnofsky Performance Scale, KPSTime frame: Up to approximately 52 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing TianTan Hospital,Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.